Key result
Candesartan had no effect on atrial electrical remodelling (half time for fall of AERP 22.0 vs 22.3 h; p=ns) or 'second factors' in a goat model of lone atrial fibrillation.
Why the study?
Does candesartan prevent atrial electrical and structural remodelling in a goat burst-paced model of atrial fibrillation?
Does candesartan prevent atrial electrical and structural remodelling in a goat burst-paced model of atrial fibrillation?
Candesartan does not prevent atrial electrical or structural remodelling in a goat model of lone AF, suggesting that clinical benefits of RAS blockade in AF are unlikely due to direct effects on atrial remodelling.
Candesartan showed no effect on AF stability in this goat model; leaves open whether RAS blockade slows clinical AF progression.
Atrial fibrillation (AF) is self-perpetuating, via mechanisms of acute electrical remodelling and 'second factors' acting over a longer time course. Renin-angiotensin system (RAS) blockade may inhibit AF self-perpetuation. We evaluated the effects of RAS blockade with candesartan in a burst-paced goat model of lone AF in which both mechanisms are known to operate. Bioactivity of oral candesartan was demonstrated in 10 goats by inhibition of the pressor effect of angiotensin II. The effects of candesartan on electrical remodelling were assessed in 12 placebo and 12 candesartan-treated goats in a 28-day burst pacing protocol. To assess the effects of candesartan on second factors (structural remodelling), 16 goats underwent further 28-day periods of burst pacing (two periods in 16 goats, three periods in eight goats) each separated by periods of sinus rhythm sufficient for electrical remodelling to reverse. There was a progressive rise in angiotensin levels in both groups. Candesartan (0.5 mg/kg/day) achieved a 76% blunting of the pressor effect of angiotensin II and had no effect on electrical remodelling; the half time for fall of atrial effective refractory period (AERP) was 22.3 ± 4.9 h (placebo) and 22.0 ± 3.2 h (candesartan) (p = ns). Candesartan had no effect on AF stability, which progressively increased over successive 28-day periods (ANOVA p < 0.05). Candesartan had no effect on atrial electrical remodelling or the operation of 'second factors' in a goat model of lone AF. These findings suggest that any benefits of RAS blockade in patients with AF are unlikely to be due to direct effects on atrial remodelling.
No takes yet. Share an insight, caveat, or question.
Hall et al. (2010) studied Atrial fibrillation (n=24). Candesartan vs. Placebo was evaluated on Half time for fall of atrial effective refractory period (AERP) (p=ns). Candesartan had no effect on atrial electrical remodelling (half time for fall of AERP 22.0 vs 22.3 h; p=ns) or 'second factors' in a goat model of lone atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: